Editorials
Defining the Mechanism of Action of Herbal Therapies in Rheumatoid Arthritis: Is This the Road to Clinical Development and Acceptance?
N. Mookherjee, H. El-Gabalawy .............................................. 1817
Inclusion Criteria Based on DAS28 Score: Strength of Improvement Is Less Dependent on Baseline Disease Activity Than Expected I. van der Horst-Bruinsma ................................................. 1820
Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus V. Strand, A.D. Chu ....................................................... 1821

Reviews
Smoking and Outcomes After Knee and Hip Arthroplasty: A Systematic Review J.A. Singh ................................................................. 1824

Articles
Plectranthus amboinicus Attenuates Inflammatory Bone Erosion in Mice with CIA by Downregulation of RANKL-induced NFATc1 Expression Y-C. Hsu, C-P. Cheng, D-M. Chang ............................................. 1844
Efficacy and Safety of CH-1504, a Metabolically Stable Antifolate, in Patients with Active RA: Results of a Phase II Multicenter Randomized Study E.C. Keystone, V.S. Shirinsky, L.S. Simon, S. Pedder, L.A. Hewitt, and the CH-1504 Study Group .................................................. 1875
Expression of APRIL in Diffuse Large B Cell Lymphomas from Patients with SLE and RA B. Lölström, C. Backlin, T. Pettersson, I.E. Lundberg, E. Baecklund ............................................. 1891
Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to SLE? Z. Touma, D.D. Gladman, D. Ibañez, M.B. Urowitz .................................. 1898
The Potential Role of Interferon-regulatory Factor 7 Among Taiwanese Patients with SLE L-H. Lin, P. Ling, M-F. Liu ................................................................. 1914
Validation of the UCLA Scleroderma Clinical Trial GI Tract Instrument Version 2.0 for SSc M. Baron, M. Hudson, R. Steele, E. Lo, and the Canadian Scleroderma Research Group ................................................................. 1925
Raynaud’s Phenomenon in Medical Laboratory Workers Who Work with Solvents G.L. Purdie, D.J. Purdie, A.A. Harrison ................................................................. 1940
High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of IFN-γ A. Antonelli, C. Ferri, S.M. Ferrari, et al ................................................................. 1947
Clinical Correlates of Urolithiasis in AS N.L. Lui, A. Carty, N. Haroon, H. Shen, R.J. Cook, R.D. Inman ................................................................. 1953
Safety and Efficacy of Fexofenadine Treatment in Subjects with Gout and Severe Allopurinol Adverse Reactions S. Cho Han ................................................................. 1957
Association of Baseline Knee Bone Size, Cartilage Volume, and BMI with Knee Cartilage Loss Over Time: A Longitudinal Study in Younger or Middle-aged Adults B. Antony, C. Ding, O. Stannius, F. Cicuttini, G. Jones ................................................................. 1973
Pediatric Rheumatology

Soluble Receptor for Advanced Glycation Endproducts Is Decreased in Patients with JIA (ERA Category) and Inversely Correlates with Disease Activity and SI100A12 Levels. A. Myles, V. Viswanath, Y.P. Singh, A. Aggarwal. 1994


Images in Rheumatology


Cryptogenic Organizing Pneumonia Mimicking Malignancy in a Patient with RA. M. Konsta, V-K. Bournia, P. Alexandrou, A. Iliopoulos. 2007

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4-8, 2010

Biomarker and Imaging Outcomes


Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials. R.B.M. Landewé, V. Strand, P.G. Conaghan, D.M. van der Heijde. 2018

MRI in RA Clinical Trials: Emerging Patterns Based on Recent Experience. C.G. Peterfy, P. Countryman, A. Gabriele, et al. 2023

Update on Research and Future Directions of the OMERACT MRI Inflammatory Arthritis Group. P.G. Conaghan, F.M. McQueen, P. Bird, et al. 2031

The OMERACT Psoriatic Arthritis MRI Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop. P. Boyesen, F.M. McQueen, F. Gandjbakhch, et al. 2034

Synovitis and Osteitis Are Very Frequent in RA Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State. F. Gandjbakhch, P.G. Conaghan, B. Ejbjerg, et al. 2039


OMERACT MRI Initiative on Structural and Inflammatory Lesions in AS — Report of a Special Interest Group at OMERACT 10 on SI Joint and Spine Lesions. X. Baraliakos, D.M. van der Heijde, J. Braun, R.B.M. Landewé. 2051

A Systematic Literature Review Analysis of Ultrasound Joint Count and Scoring Systems to Assess Synovitis in RA According to the OMERACT Filter. P. Mandl, E. Naredo, R.J. Wakefield, P.G. Conaghan, M.A. D’Agostino, on behalf of the OMERACT Ultrasound Task Force. 2055

The OMERACT Ultrasound Task Force — Status and Perspectives. E. Naredo, R.J. Wakefield, A. Iagnocco, et al. 2063


Correspondence

Subclinical Atherosclerosis in AS. M.A. Gonzalez-Gay, C. Gonzalez-Juanatey, J. Llorca. 2073

Reply. Z. Szekanecz, N. Bodnár, S. Szántó, G. Kerekes, P. Soltész. 2073


Reply. R. Rajbhandary, A. Khezri, R.S. Panush. 2074

The Modification of the ACR Preliminary Diagnostic Criteria for FM Should Be Supplemented and Revised. K. Toda. 2075

Reply. F. Wolfe. 2075

Prevalence of Chronic Rheumatic Diseases in Mexico. C. Abud-Mendoza, A. Sánchez-Arriaga, M. Martinez-Martinez. 2076

Reply. M.H. Cardiel. 2076

Letters

Minimal Important Difference and Responsiveness to Change of the SF-36 in Patients with PsA Receiving TNF-α Blockers. Y.Y. Leung, T.Y. Zhu, L.S. Tam, E.W-L. Kun, E.K-M. Li. 2077


IL-6 Blockade as Steroid-sparing Treatment for 2 Patients with GCA. S. Sciascia, D. Rossi, D. Roccatello. 2080

Combined Pulmonary Fibrosis and Emphysema Syndrome in a Patient Age 28 Years with Severe SSc. V. Cottin, N. Freymond, J. Cabane, J-F. Cordier. 2082

Marked Reduction of SI Joint Inflammation on MRI in a Patient with AS After Rituximab Treatment. Y. Huang, F. Cheng, X. Zhang, J. Tang. 2083

Correction


Meetings in Rheumatology . . . . . . . . . . . . . . . . . . . . . . . . xii